학술논문
PLOD1 acts as a tumor promoter in glioma via activation of the HSF1 signaling pathway
Document Type
Academic Journal
Author
Source
Molecular and Cellular Biochemistry. February, 2022, Vol. 477 Issue 2, p549, 9 p.
Subject
Language
English
ISSN
0300-8177
Abstract
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (PLOD1) is a collagen-related lysyl hydroxylase and its prognostic value in glioma patients was verified. However, its biological function in glioma has yet to be fully investigated. The PLOD1 mRNA status and clinical significance in gliomas were assessed via the GEPIA database. Overexpression or targeted depletion of PLOD1 was carried out in the human glioma cell line U87 and verified by western blotting. CCK8 and colony formation assays were implemented to examine the impact of PLOD1 on the proliferative and colony-forming phenotypes of U87 cells. Luciferase reporter assays and HSF1-specific pharmacologic inhibitors (KRIBB11) were employed to determine the regulatory relationship between PLOD1 and heat shock factor 1 (HSF1). High expression of PLOD1 was observed in tissue samples of glioblastoma multiforme (GBM) and brain lower-grade glioma (LGG). GEPIA overall survival further demonstrated that both GBM and LGG patients with high PLOD1 displayed worse clinical outcomes compared with those with low PLOD1. Overexpression and targeted depletion of PLOD1 enhanced and suppressed U87 cell proliferation and colony formation, respectively. Luciferase reporter assays showed that PLOD1 significantly enhanced the transcriptional activity of HSF1 in HEK293T cells. PLOD1 deficiency in U87 cells inhibited HSF1-induced survivin accumulation, whereas KRIBB11 also blocked the PLOD1-overexpressing induced survivin expression. An inhibitor of HSF1 signaling events abolished the increased clonogenic potential caused by PLOD1 overexpression in U87 cells. High expression of PLOD1 can increase the proliferation and colony formation of U87 cells by activating the HSF1 signaling pathway. This study suggested PLOD1/HSF1 as an effective therapeutic target for gliomas.
Author(s): Bo Yuan [sup.1], Yimin Xu [sup.1], Shaoqin Zheng [sup.1] Author Affiliations: (1) grid.411679.c, 0000 0004 0605 3373, Department of Neurosurgery, The First Affiliated Hospital, Shantou University Medical College, , [...]
Author(s): Bo Yuan [sup.1], Yimin Xu [sup.1], Shaoqin Zheng [sup.1] Author Affiliations: (1) grid.411679.c, 0000 0004 0605 3373, Department of Neurosurgery, The First Affiliated Hospital, Shantou University Medical College, , [...]